This post has been self-published on Youth Ki Awaaz by Tanuja Aundhe. Just like them, anyone can publish on Youth Ki Awaaz.

Modi Sarkar’s Flirtation With Drug Prices: Punishment For Illness Or Deregulation For Betterment?

More from Tanuja Aundhe

By Tanuja Aundhe:

Medication is, to put it simply, one of the most important things in life. Of course, it comes in many forms (in re: laughter is the best medicine), but, you know, we literally cannot live without it. Medicine, I mean. But laughter too, of course. India is one of the countries in the world with incidences of illnesses of all kinds, ranging from asthma, to diabetes to tuberculosis, increasing day by day. At last count, there were around 4.1 crore diabetes patients, 5.7 crore coronary heart disease patients, 22 lakh TB patients, 11 lakh cancer patients, 25 lakh HIV/AIDS patients and 6 crore blood pressure patients in India.


So, well, drugs and their prices in India have always been one of the most hotly debated topics (what’s that you say? No, not those drugs. Get your mind out of the gutter). Drug prices in India vary based on a number of factors, just as in any other country — the availability of the particular drug in the market, the state of the market itself at the time, whether the drug is classified as ‘essential’ or not, and so on. There is a National List of Essential Medicine (NLEM) published by the central government, which sets the maximum limits on drug prices, for essential medicines (obviously). The latest one was published in 2013 and contained 348 names.

However, the big daddy in this field, the regulatory body, is the National Pharmaceutical Pricing Authority (NPPA), set up in 1997. This authority has the power to set caps on drug prices, to limit and extend medicine sales, and so on, under the Drug Prices Control Order (DPCO) 2013. The DPCO also incorporates the NLEM stated above, with several more drugs added to the list. Some sources say that the number of medicines under DPCO are at above 600.

Additionally, under paragraph 19 of the DPCO, the NPPA is allowed to set caps on the prices of non-essential drugs, and has internal guidelines which allow it to do the same, which were put in place in May of this year. In July 2014, accordingly, it issued a list of 108 drugs which were non-essential, but now had price caps, in order to avoid competition and excessively high prices because of differences between brands.

Now, near the end of September 2014, the NPPA’s aforementioned power under paragraph 19 to set caps on certain drug prices was withdrawn, on the basis of advice reportedly given by the Solicitor General of India, Ranjit Kumar. How was this done? Remember those internal guidelines? Those had been set with the help of the central government, and were withdrawn on suggestions received from the same. It was said that the caps set in July 2014 would not be affected, though reports are suggestive that they are, and will continue, being affected. The drugs whose prices had been controlled under the July 2014 notification included a variety of medications, from a cancer drug (Glivec) to an anti-rabies drug (Kamrab), to a blood pressure medicine (Plavix).

Immediately, rumours started running around the Indian markets, going from maddening and terrifying, to much worse. One oft-quoted statement was that the price of Glivec, a cancer drug produced and marketed by Novartis, had risen from somewhere near Rs.8000 to something like Rs.1.08 lakh. Whoa! There was immediately a lawsuit instituted about this, in the Supreme Court. The lawsuit also stated that the decontrol in prices would negate the Indians’ Right to Life and Livelihood, a fundamental right granted by the Indian Constitution. (Oh yes, this is that Glivec, by the way. The famous patent lawsuit was about this one only. For more information, see: Novartis v. Union of India and Others)

How true is this rumour? We can’t say. But well, of course, the timing of this decontrol of prices was highly suspect, given that the new central government in India took over in May 2014, just a few days before the internal guidelines were set up. For some people, it feels like the moment it could, the government turned its attention to the NPPA, and went about maximising profit, keeping in mind the poor, needy pharmaceutical companies, rather than the very well-off but sadly sick electorate. Of course that’s how it happened. Seems like a Pyrrhic victory, doesn’t it?

However, this rumour is certainly questionable. For one, the NPPA is still allowed to regulate the prices of drugs. Only the internal guidelines have been withdrawn. For another, the central government still has the power to regulate drug prices, thanks to Section 3 of the Essential Commodities Act, 1955. It is worth noting here, though, keeping in mind the pending litigation, that it is unknown whether the NPPA can still use their power under paragraph 19 of the DPCO or not.

By the way, knowing Indian politics, there was immediately a bit of warmongering on the part of our favourite politicians. Rahul Gandhi got annoyed and said that it’s all a ploy by the Modi government, to which the BJP replied, ‘he’s disgruntled because he just lost the elections’. (I paraphrase. Forgive me, reader.)

What about the pharmaceutical companies, though? We’ve covered the other stakeholders, the government and the NPPA, the patients (the lawsuit), and now all we have left to consider is the sellers of these drugs.

The industry, in general, welcomed these proceedings (Do I even need to say duh here?). They said that they had always felt that paragraph 19 was erroneous (yep), and it wasn’t the appropriate provision to be invoked, and so on. To wit, a Mr Dilip G Shah, secretary general of the Indian Pharmaceutical Alliance: “We have always contended that the guidelines for Para 19 were erroneous. Para 19 is not the right provision for extension of price control as there is no public health concern which could have prompted the NPPA to invoke the provision.”

This same Mr Shah had also said  that “several companies have started withdrawing their products that are under price control, which means availability is going down.”

He cited the example of antibiotic drug Augmentin, whose price had been capped under the July 2014 notification. Under this cap, a lot of generic manufacturers had shut down production, which meant that the market share of its inventor, GlaxoSmithKline, had increased.

Another group of pharma companies under the head of the Organisation of Pharmaceutical Producers of India, said as follows:

“We appreciate the government’s decision to withdraw the guidelines on fixation/revision of prices of scheduled and non-scheduled formulations under Para 19 of the DPCO 2013. This welcome move tells us we are being heard and we look forward to working with the government toward a common goal.”

This above statement, along with a bit of common sense, offers the following meaning — that these companies can take this move as a chance to jack up R&D in India, to allow for more generic and unique drugs to be created, and thus, have a ‘common goal’ with the Indian government to have a healthy and happy Indian public (Yeah. And then we’ll all play with our pet unicorns and sing).

It was obvious that the decision made in July must have affected the profits of some big industry players such as Ranbaxy Laboratories Ltd, Pfizer Inc, Novartis, Abbott Laboratories, Sanofi SA, Merck & Co Inc, among others. The change in September was definitely much wanted (They could hear the pops of the champagne corks all the way to Macau, apparently). They had argued against the change at the beginning itself, by saying that most of these drugs were against lifestyle diseases, thus non-essential, and their price must not be controlled. That turned out to be a bit of a moot point because, well, their status as non-essential (as deemed by the Indian legislature and government) was never under question. The NPPA had the power to regulate their prices anyway too. They said it, regardless. Moving on, they had also used the argument that a regulator has no role to play in a free market (Capitalist economy zindabad).

The share prices of several drug companies shot up after the change in September. Sun Pharma and Ranbaxy gained nearly 2 per cent and GSK Pharma and Davis Lab gained 1 per cent each. Glenmark was also up around 1 per cent.

You know what? I get it. I get it, totally. All of this smells of a steaming conspiracy to help multinational drug companies earn massive profits off the poor ailing people while we rot in our poverty. This is totally not so that deregulation of markets, and free markets, can actually be a thing in India. This is definitely not going to help strengthen India’s international ties, so that it will be easier to lure more big players to enter our market. Of course it isn’t going to support the Indian home-grown pharmaceutical companies, or foster more grass-roots innovation, or allow our market to grow more easily. Oh, no. It’s all the Illuminati.

You must be to comment.
  1. Gaurav

    Accusing the Modi government of working for “big businessmen,” Rahul Gandhi had alleged that it lifted control on drug prices at the behest of some US companies which has led to cancer medicines costing over Rs 1 lakh instead of Rs 8000 earlier. but this is not true as the number of drugs whose prices are kept under control was 440 before BJP came to power and now their count is 489. The prices of 108 non-scheduled drugs meant for treatment of cancer, diabetes or cardiovascular diseases have come down by 30 % providing relief to people all over india, wonder why the writer did not do her research properly, such anti establishment articles are to be found in large numbers these days, indian writers should learn to demonstrate integrity

More from Tanuja Aundhe

Similar Posts

By Pushpendra Singh

By YLAC India

By Avinash Tavares

Wondering what to write about?

Here are some topics to get you started

Share your details to download the report.

We promise not to spam or send irrelevant information.

Share your details to download the report.

We promise not to spam or send irrelevant information.

An ambassador and trained facilitator under Eco Femme (a social enterprise working towards menstrual health in south India), Sanjina is also an active member of the MHM Collective- India and Menstrual Health Alliance- India. She has conducted Menstrual Health sessions in multiple government schools adopted by Rotary District 3240 as part of their WinS project in rural Bengal. She has also delivered training of trainers on SRHR, gender, sexuality and Menstruation for Tomorrow’s Foundation, Vikramshila Education Resource Society, Nirdhan trust and Micro Finance, Tollygunj Women In Need, Paint It Red in Kolkata.

Now as an MH Fellow with YKA, she’s expanding her impressive scope of work further by launching a campaign to facilitate the process of ensuring better menstrual health and SRH services for women residing in correctional homes in West Bengal. The campaign will entail an independent study to take stalk of the present conditions of MHM in correctional homes across the state and use its findings to build public support and political will to take the necessary action.

Saurabh has been associated with YKA as a user and has consistently been writing on the issue MHM and its intersectionality with other issues in the society. Now as an MHM Fellow with YKA, he’s launched the Right to Period campaign, which aims to ensure proper execution of MHM guidelines in Delhi’s schools.

The long-term aim of the campaign is to develop an open culture where menstruation is not treated as a taboo. The campaign also seeks to hold the schools accountable for their responsibilities as an important component in the implementation of MHM policies by making adequate sanitation infrastructure and knowledge of MHM available in school premises.

Read more about his campaign.

Harshita is a psychologist and works to support people with mental health issues, particularly adolescents who are survivors of violence. Associated with the Azadi Foundation in UP, Harshita became an MHM Fellow with YKA, with the aim of promoting better menstrual health.

Her campaign #MeriMarzi aims to promote menstrual health and wellness, hygiene and facilities for female sex workers in UP. She says, “Knowledge about natural body processes is a very basic human right. And for individuals whose occupation is providing sexual services, it becomes even more important.”

Meri Marzi aims to ensure sensitised, non-discriminatory health workers for the needs of female sex workers in the Suraksha Clinics under the UPSACS (Uttar Pradesh State AIDS Control Society) program by creating more dialogues and garnering public support for the cause of sex workers’ menstrual rights. The campaign will also ensure interventions with sex workers to clear misconceptions around overall hygiene management to ensure that results flow both ways.

Read more about her campaign.

MH Fellow Sabna comes with significant experience working with a range of development issues. A co-founder of Project Sakhi Saheli, which aims to combat period poverty and break menstrual taboos, Sabna has, in the past, worked on the issue of menstruation in urban slums of Delhi with women and adolescent girls. She and her team also released MenstraBook, with menstrastories and organised Menstra Tlk in the Delhi School of Social Work to create more conversations on menstruation.

With YKA MHM Fellow Vineet, Sabna launched Menstratalk, a campaign that aims to put an end to period poverty and smash menstrual taboos in society. As a start, the campaign aims to begin conversations on menstrual health with five hundred adolescents and youth in Delhi through offline platforms, and through this community mobilise support to create Period Friendly Institutions out of educational institutes in the city.

Read more about her campaign. 

A student from Delhi School of Social work, Vineet is a part of Project Sakhi Saheli, an initiative by the students of Delhi school of Social Work to create awareness on Menstrual Health and combat Period Poverty. Along with MHM Action Fellow Sabna, Vineet launched Menstratalk, a campaign that aims to put an end to period poverty and smash menstrual taboos in society.

As a start, the campaign aims to begin conversations on menstrual health with five hundred adolescents and youth in Delhi through offline platforms, and through this community mobilise support to create Period Friendly Institutions out of educational institutes in the city.

Find out more about the campaign here.

A native of Bhagalpur district – Bihar, Shalini Jha believes in equal rights for all genders and wants to work for a gender-equal and just society. In the past she’s had a year-long association as a community leader with Haiyya: Organise for Action’s Health Over Stigma campaign. She’s pursuing a Master’s in Literature with Ambedkar University, Delhi and as an MHM Fellow with YKA, recently launched ‘Project अल्हड़ (Alharh)’.

She says, “Bihar is ranked the lowest in India’s SDG Index 2019 for India. Hygienic and comfortable menstruation is a basic human right and sustainable development cannot be ensured if menstruators are deprived of their basic rights.” Project अल्हड़ (Alharh) aims to create a robust sensitised community in Bhagalpur to collectively spread awareness, break the taboo, debunk myths and initiate fearless conversations around menstruation. The campaign aims to reach at least 6000 adolescent girls from government and private schools in Baghalpur district in 2020.

Read more about the campaign here.

A psychologist and co-founder of a mental health NGO called Customize Cognition, Ritika forayed into the space of menstrual health and hygiene, sexual and reproductive healthcare and rights and gender equality as an MHM Fellow with YKA. She says, “The experience of working on MHM/SRHR and gender equality has been an enriching and eye-opening experience. I have learned what’s beneath the surface of the issue, be it awareness, lack of resources or disregard for trans men, who also menstruate.”

The Transmen-ses campaign aims to tackle the issue of silence and disregard for trans men’s menstruation needs, by mobilising gender sensitive health professionals and gender neutral restrooms in Lucknow.

Read more about the campaign here.

A Computer Science engineer by education, Nitisha started her career in the corporate sector, before realising she wanted to work in the development and social justice space. Since then, she has worked with Teach For India and Care India and is from the founding batch of Indian School of Development Management (ISDM), a one of its kind organisation creating leaders for the development sector through its experiential learning post graduate program.

As a Youth Ki Awaaz Menstrual Health Fellow, Nitisha has started Let’s Talk Period, a campaign to mobilise young people to switch to sustainable period products. She says, “80 lakh women in Delhi use non-biodegradable sanitary products, generate 3000 tonnes of menstrual waste, that takes 500-800 years to decompose; which in turn contributes to the health issues of all menstruators, increased burden of waste management on the city and harmful living environment for all citizens.

Let’s Talk Period aims to change this by

Find out more about her campaign here.

Share your details to download the report.

We promise not to spam or send irrelevant information.

A former Assistant Secretary with the Ministry of Women and Child Development in West Bengal for three months, Lakshmi Bhavya has been championing the cause of menstrual hygiene in her district. By associating herself with the Lalana Campaign, a holistic menstrual hygiene awareness campaign which is conducted by the Anahat NGO, Lakshmi has been slowly breaking taboos when it comes to periods and menstrual hygiene.

A Gender Rights Activist working with the tribal and marginalized communities in india, Srilekha is a PhD scholar working on understanding body and sexuality among tribal girls, to fill the gaps in research around indigenous women and their stories. Srilekha has worked extensively at the grassroots level with community based organisations, through several advocacy initiatives around Gender, Mental Health, Menstrual Hygiene and Sexual and Reproductive Health Rights (SRHR) for the indigenous in Jharkhand, over the last 6 years.

Srilekha has also contributed to sustainable livelihood projects and legal aid programs for survivors of sex trafficking. She has been conducting research based programs on maternal health, mental health, gender based violence, sex and sexuality. Her interest lies in conducting workshops for young people on life skills, feminism, gender and sexuality, trauma, resilience and interpersonal relationships.

A Guwahati-based college student pursuing her Masters in Tata Institute of Social Sciences, Bidisha started the #BleedwithDignity campaign on the technology platform, demanding that the Government of Assam install
biodegradable sanitary pad vending machines in all government schools across the state. Her petition on has already gathered support from over 90000 people and continues to grow.

Bidisha was selected in’s flagship program ‘She Creates Change’ having run successful online advocacy
campaigns, which were widely recognised. Through the #BleedwithDignity campaign; she organised and celebrated World Menstrual Hygiene Day, 2019 in Guwahati, Assam by hosting a wall mural by collaborating with local organisations. The initiative was widely covered by national and local media, and the mural was later inaugurated by the event’s chief guest Commissioner of Guwahati Municipal Corporation (GMC) Debeswar Malakar, IAS.

Sign up for the Youth Ki Awaaz Prime Ministerial Brief below